Wells Fargo’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-32,479
Closed -$749K – 7767
2020
Q4
$749K Buy
32,479
+22,979
+242% +$291K ﹤0.01% 4235
2020
Q3
$97K Sell
9,500
-1,628
-15% -$21.8K ﹤0.01% 5280
2020
Q2
$166K Sell
11,128
-10,240
-48% -$158K ﹤0.01% 5006
2020
Q1
$260K Buy
21,368
+9,225
+76% +$147K ﹤0.01% 4509
2019
Q4
$192K Buy
12,143
+7,643
+170% +$97.5K ﹤0.01% 4976
2019
Q3
$55K Buy
+4,500
New +$51K ﹤0.01% 5538

Wells Fargo's PRVL Position: Q1 2021 in Review

Wells Fargo sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 32,479 shares — an estimated $749K sold.

Wells Fargo first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $749K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Wells Fargo reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Wells Fargo sold 32,479 Prevail Therapeutics shares in Q1 2021, an estimated $749K.
  • Wells Fargo first reported a position in Prevail Therapeutics in Q3 2019 and held it in 6 quarters.
  • Wells Fargo's Prevail Therapeutics position peaked at $749K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.

Based on Wells Fargo's 13F filing for Q1 2021, filed 13 May 2021.